Pharmaceutics
Multi-Cycle Dosimetry of the Albumin-Binding Prostate-Specific Membrane Antigen Ligand [177Lu]Ludotadipep in Metastatic Androgen Pathway Modulator-Resistant Prostate Cancer with Adjusted Red Marrow Modeling
By Seunggyun Ha, Joo Hyun O, Chansoo Park and 6 others.
Abstract
Purpose
This dosimetry study aimed to evaluate the organ-absorbed doses and safety profile of multiple doses of [177Lu]Ludotadipep, a novel PSMA-targeted radiopharmaceutical with an albumin-binding motif, in patients with metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer.
Methods
Twenty patients received a total of 68 cycles of [177Lu]Ludotadipep (3.70 GBq/cycle, up to six cycles, 8-week intervals), and dosimetry analysis was done for 67 cycles. Organ-absorbed doses were estimated using planar and SPECT/CT imaging and blood-based methods. Red marrow dose was calculated using a red marrow-to-blood activity concentration ratio (RMBLR) derived from a hematocrit-adjusted model for large molecules and cross-checked by comparison with data derived from quantitative SPECT/CT images and blood samples.